ORAGENICS INC OGEN
are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies
targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization
of its lead product candidate, ONP-002. Our lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic,
and we believe it can cross the blood-brain barrier with the goal of rapidly eliminating swelling, oxidative stress and inflammation
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $37.7K | $131.5K | $87.0K | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 |
| R&D | $2.4M | $4.1M | $15.5M | $10.1M | $10.6M | $22.1M | $12.1M | $6.0M | $3.5M | $4.8M |
| SG&A | $7.0M | $6.4M | $5.5M | $4.5M | $5.3M | $4.5M | $3.8M | $4.0M | $3.2M | $3.8M |
| Total operating expenses | $9.4M | $10.6M | $20.9M | $14.6M | $15.9M | $26.6M | $15.9M | $10.0M | $6.7M | $8.5M |
| Operating income | -$9.4M | -$10.6M | -$20.9M | -$14.4M | -$15.8M | -$26.6M | -$15.9M | -$10.0M | -$6.7M | -$8.5M |
| Interest expense | $785.9K | $29.8K | $30.6K | $15.1K | $15.8K | $10.7K | $7.3K | $5.8K | $216.3K | $4.1K |
| Pre-tax income | -$10.0M | -$10.6M | -$20.7M | -$14.3M | -$15.7M | -$26.4M | -$15.6M | -$9.9M | -$6.7M | -$8.5M |
| Income tax | $136.9K | — | — | — | — | — | — | $0 | $0 | $0 |
| Net income | -$984.2M | -$1.06B | -$20.7M | -$14.3M | -$15.7M | -$26.4M | -$15.6M | -$9.9M | -$6.7M | -$7.0M |
| EPS, basic | -4.56 | -47.88 | -9.18 | -7.11 | -8.09 | -0.47 | — | — | — | — |
| EPS, diluted | -4.56 | -47.88 | -9.18 | -7.11 | -0.14 | -0.47 | -0.37 | -0.87 | -1.37 | -1.57 |
| Shares, diluted (wtd. avg.) | $2.2M | $220.7K | $2.2M | $2.0M | $1.9M | $56.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.4M | $864.8K | $3.5M | $11.4M | $27.3M | $17.6M | $18.3M | $20.2M | $6.2M | $4.1M |
| Short-term investments | $4.0M | — | — | — | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | — | — | $0 |
| Inventory | — | — | — | — | — | — | — | — | — | $0 |
| Total current assets | $10.1M | $1.5M | $3.9M | $14.3M | $27.7M | $18.0M | $18.8M | $21.9M | $7.2M | $4.2M |
| Property, plant and equipment | — | — | $0 | $121.1K | $45.7K | $42.7K | $92.0K | $116.3K | $21.7K | $87.5K |
| Total assets | $10.1M | $1.5M | $5.0M | $14.8M | $28.2M | $18.7M | $19.8M | $22.0M | $7.2M | $4.3M |
| Accounts payable | $1.6M | $1.4M | $1.5M | $1.1M | $947.6K | $937.0K | $1.5M | $1.0M | $818.0K | $1.3M |
| Total current liabilities | — | — | $1.8M | $1.6M | $1.4M | $1.3M | $1.9M | $1.2M | $898.5K | $1.3M |
| Total liabilities | $1.8M | $1.7M | $1.8M | — | — | — | — | — | — | — |
| Retained earnings | -$226.6M | -$216.8M | -$206.2M | -$185.6M | -$171.3M | -$154.4M | -$127.4M | -$111.4M | -$101.4M | -$94.7M |
| Total equity | $8.3M | -$211.9K | $3.2M | $13.0M | $26.5M | $16.8M | $17.2M | $20.9M | $6.3M | $3.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$8.6M | -$7.3M | -$15.2M | -$13.5M | -$17.0M | -$13.0M | -$9.1M | -$6.4M | -$7.1M |
| Stock-based compensation | $642.4K | $516.0K | $1.0M | $742.2K | $1.7M | $1.5M | $553.0K | $996.0K | — | — |
| Capital expenditure | — | — | — | $127.5K | $43.9K | — | $25.2K | $124.7K | — | $27.2K |
| Investing cash flow | — | — | -$936.3K | -$115.5K | -$43.9K | — | -$25.2K | -$124.7K | — | $1.7M |
| Financing cash flow | $16.8M | $6.0M | $283.9K | -$494.9K | $23.1M | $16.3M | $11.1M | $23.2M | $8.4M | $4.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-024602.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |